- Teva maintains its full-year revenue forecast at $16.8 billion to $17.2 billion, with a current estimate of $16.9 billion.
- Earnings per share (EPS) for the full year are projected between $2.50 and $2.65.
- Adjusted EBITDA for the full year is expected to be between $4.7 billion and $5.0 billion, matching an estimate of $4.86 billion.
- Forecasted free cash flow remains at $1.6 billion to $1.9 billion.
- In the second quarter, Teva reported adjusted EPS of 66 cents and a revenue of $4.18 billion, slightly below the $4.27 billion estimate.
- Teva’s North American revenues for Austedo reached $495 million, while Treanda & Bendeka accounted for $40 million.
- Copaxone generated $62 million in North America, $50 million in Europe, and $7 million internationally.
- The company’s adjusted EBITDA for Q2 was $1.23 billion, exceeding the estimated $1.18 billion.
- Teva’s current debt stands at $17.23 billion, and its reported EPS is 24 cents.
- Teva is expecting to launch two new products in the second half of 2025.
- The company is committed to doubling its biosimilar revenues between 2024 and 2027.
- Teva is actively pursuing the sale of its active-pharmaceutical ingredient business.
- Aiming to deliver approximately $700 million in net savings, with about $70 million anticipated in 2025.
- Transformation programs combined with product growth aim to achieve a 30% operating margin target by 2027.
- Market sentiment reflects 10 buy recommendations, 0 holds, and 1 sell recommendation.
A look at Teva Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts assessing Teva Pharmaceutical Industries using Smartkarma Smart Scores have given the company a mixed outlook for the long term. While Teva scores moderately in areas like value and momentum with scores of 3, indicating fair value and decent momentum, its scores in dividend, growth, and resilience fall on the lower end at 1, 2, and 2 respectively. This suggests that Teva may not be a top choice for investors seeking high dividends or strong growth potential, although it shows promise in terms of value and momentum.
Teva Pharmaceutical Industries Limited, a global pharmaceutical company, is known for its development, manufacturing, and marketing of both generic and branded human pharmaceuticals, along with active pharmaceutical ingredients. With a reach that extends to customers worldwide, Teva maintains a presence in various segments of the pharmaceutical industry, aiming to cater to a broad market base with its diverse product offerings.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
